文献速递骨质疏松与代谢性骨病关节外科

罗莫佐单抗对伴或不伴类风湿关节炎合并症绝经后骨质疏松患者的差异化疗效研究:一项病例对照研究

An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
PubMed 文献 · Osteoporos Int · 2024-01-31

这项回顾性、病例对照、多中心研究纳入171例未口服糖皮质激素的绝经后骨质疏松患者(RA组59例,非RA组121例),均接受罗莫佐单抗治疗12个月,倾向性评分匹配后每组41例。结果显示RA组腰椎和全髋骨密度增幅均低于非RA组,且ACPA滴度与腰椎骨密度变化、HAQ-DI与股骨颈骨密度变化呈负相关。作者认为罗莫佐单抗的疗效可能被RA相关因素减弱。

要点

  • 匹配后RA组腰椎骨密度12个月增幅9.1%,低于非RA组的12.6%(P=0.013)。
  • 匹配后RA组全髋骨密度12个月增幅2.4%,低于非RA组的4.8%(P=0.025)。
  • RA组PINP升幅和TRACP-5b降幅均呈现小于非RA组的趋势,提示合成代谢窗更小。

核心结论

  • 罗莫佐单抗的疗效可能被类风湿关节炎相关因素减弱。

研究设计与样本

  • 回顾性、病例对照、多中心研究,纳入171例未口服糖皮质激素的绝经后骨质疏松患者,其中RA组59例、非RA组121例,均接受罗莫佐单抗不间断治疗12个月。
  • 采用倾向性评分匹配确保临床背景可比,匹配后每组41例;基线总体平均年龄76.3岁,腰椎T值-3.0,45.1%为骨质疏松初治患者。
  • RA组基线抗环瓜氨酸肽抗体(ACPA)阳性率80.5%,滴度206.2 U/ml,临床疾病活动指数(CDAI)13.6,健康评估问卷残疾指数(HAQ-DI)0.9。
  • 在12个月期间监测骨密度和血清骨转换标志物。

主要发现

  • 骨形成标志物PINP的升高幅度和骨吸收标志物TRACP-5b的降低幅度在RA组均呈现小于非RA组的趋势,提示合成代谢窗更小。
  • 治疗12个月后,RA组腰椎骨密度增幅为9.1%,非RA组为12.6%(P=0.013)。
  • 治疗12个月后,RA组全髋骨密度增幅为2.4%,非RA组为4.8%(P=0.025)。
  • 在全部RA组(n=59)中行多元回归分析,ACPA滴度与腰椎骨密度变化呈负相关,HAQ-DI与股骨颈骨密度变化呈负相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The impact of ROMO on the width of anabolic windows and the increase in BMD was reduced in the RA group compared to the non-RA group, and this reduction was associated with correlations to RA-related factors. PURPOSE: To investigate the effects of romosozumab (ROMO) in postmenopausal osteoporosis, with and without comorbid rheumatoid arthritis (RA). METHODS: In this retrospective, case-controlled, multicenter study, 171 postmenopausal patients who did not receive oral glucocorticoid, comprising 59 in the RA group and 121 in the non-RA group, received uninterrupted ROMO treatment for 12 months. Propensity score matching was employed to ensure comparability in clinical backgrounds, resulting in 41 patients in each group. Baseline characteristics were as follows: overall (mean age, 76.3 years; T-score of lumbar spine (LS), - 3.0; 45.1% were treatment-naive for osteoporosis); RA group (anti-cyclic citrullinated peptide antibody (ACPA) positivity, 80.5%; titer, 206.2 U/ml; clinical disease activity index (CDAI), 13.6; health assessment questionnaire disability index (HAQ-DI), 0.9). Bone mineral density (BMD) and serum bone turnover markers were monitored over a 12-month period. RESULTS: The rate of increase in the bone formation marker, PINP, and the rates of decrease in the bone resorption marker, TRACP-5b, exhibited a trend toward smaller changes in the RA group compared to the non-RA group, implying a smaller anabolic window. After 12 months, the RA group displayed lower BMD increases in the LS (9.1% vs. 12.6%; P = 0.013) and total hip (2.4% vs. 4.8%; P = 0.025) compared to the non-RA group. Multiple regression analysis in the all RA group (n = 59) for the association between RA-specific factors and 12-month BMD changes revealed negative correlations between ACPA titer and LS BMD and between HAQ-DI and femoral neck BMD. CONCLUSIONS: The efficacy of ROMO may be attenuated by RA-related factors.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ebina K, Nagayama Y, Kashii M, et al. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study. Osteoporos Int. 2024. PMID: 38296866. doi:10.1007/s00198-024-07019-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。